These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4279834)

  • 1. Effect of combination treatment with mitomycin-c and lysosome labilizers on nodular pulmonary metastases.
    Niitani H; Suzuki A; Taniguchi T; Saijo N; Kawase I; Kimura K
    Gan; 1974 Oct; 65(5):403-9. PubMed ID: 4279834
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of combined therapy with lysosome labilizer and antineoplastic agents with reference to increased effect of mitomycin C by lipoprotein lipase].
    Niitani H; Inagaki J; Taniguchi T; Shimoyama M; Konda C
    Saishin Igaku; 1970 Jan; 25(1):172-6. PubMed ID: 4245860
    [No Abstract]   [Full Text] [Related]  

  • 3. [Synergic effects of lysosome labilizer and anti-neoplastic agents with special reference to the effects of plasmin and mitomycin-C].
    Niitani H; Suzuki A; Konda C; Taniguchi T; Inagaki J
    Saishin Igaku; 1968 Oct; 23(10):2168-72. PubMed ID: 4237729
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chemotherapy against pulmonary metastasis from uterine cervical carcinoma].
    Saijo N
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):992-7. PubMed ID: 6191708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of cancer--theory and practice].
    Niitani H
    Naika; 1971 Oct; 28(4):657-64. PubMed ID: 4943164
    [No Abstract]   [Full Text] [Related]  

  • 6. Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.
    Masegi T; Kato A; Kitai K; Fukuoka M; Soma K; Ichikawa Y; Nakamura S; Watanabe N; Niitsu Y
    Jpn J Cancer Res; 1993 Apr; 84(4):451-4. PubMed ID: 8514612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dextran on the fibrinolytic activity of urokinase.
    Matsuo O; Kosugi T; Mihara H
    Nihon Ketsueki Gakkai Zasshi; 1982 Feb; 45(1):112-8. PubMed ID: 6180584
    [No Abstract]   [Full Text] [Related]  

  • 8. [Potentiation of antineoplastic agents--significance of combination with urokinase].
    Yamamoto M; Yamada T; Fukunaga K; Nagashima A; Nagamatsu S
    Gan No Rinsho; 1971 Oct; 17(10):750-9. PubMed ID: 5166830
    [No Abstract]   [Full Text] [Related]  

  • 9. Local injection of antitumor agents in the gastric wall for treatment of nodal metastases of gastric carcinoma.
    Kikuchi K; Aneha Y; Kanno H; Kunii Y; Hirata K
    Tohoku J Exp Med; 1977 Jun; 122(2):121-7. PubMed ID: 888137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)].
    Yamamoto M
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1461-73. PubMed ID: 6820918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased thrombolysis and decreased platelet aggregation with an anti-GPIIb/IIIa antibody urokinase hybrid molecule (7E3-UK)].
    Bode C; Nordt T; Freitag M; Ruef J; Kaltenmeier M; Meinhardt G; Kübler W; Haber E
    Verh Dtsch Ges Inn Med; 1991; 97():1-2. PubMed ID: 1839701
    [No Abstract]   [Full Text] [Related]  

  • 12. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 13. [Experimental and clinical studies on cancer chemotherapy--enhancement of the cytocidal effect of Mitomycin-C by one of lysosome labilizer, plasmin].
    Taniguchi T
    Nihon Gan Chiryo Gakkai Shi; 1972 Dec; 7(4):290-309. PubMed ID: 4266268
    [No Abstract]   [Full Text] [Related]  

  • 14. Cooperative action of the prostacyclin analogue taprostene and the fibrinolytic prourokinase (r-scu-PA) in experimental artery thrombosis.
    Groves R; Schneider J; Flohé L
    Prog Clin Biol Res; 1989; 301():603-7. PubMed ID: 2508120
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of the thrombolytic effect of low urokinase concentrations.
    Matsuo O; Mihara H; Rokushima Y
    Nihon Ketsueki Gakkai Zasshi; 1976 Jun; 39(3):298-305. PubMed ID: 990007
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intracoronary thrombolytic therapy of acute myocardial infarction].
    Astaf'ev VI; Runovich AA; Grigor'ev EG; Kustov VI; Kuril'skaia TE
    Grudn Khir; 1985; (5):58-65. PubMed ID: 3905528
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 18. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Potentiation of mitomycin C by dextran sulfate].
    Niitani H; Taniguchi T; Konda C; Suzuki A; Kimura K
    Gan No Rinsho; 1971; 17(9):700-3. PubMed ID: 5165864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.